Glutamic Acid

Glutamic Acid

SCHEMBL3734632

C=CC(=O)C=C.N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 0.72
GRM6 O15303 2/20 0.72
GRM7 Q14831 2/20 0.72
GRM4 Q14833 2/20 0.72
GSR P00390 2/20 0.72
GRIN2D O15399 1/20 0.72
GRIN3B O60391 1/20 0.72
CYP1A2 P05177 1/20 0.72
GRIK1 P39086 1/20 0.72
GRM5 P41594 1/20 0.72
GRIA1 P42261 1/20 0.72
GRIA2 P42262 1/20 0.72
GRIA3 P42263 1/20 0.72
SLC1A3 P43003 1/20 0.72
SLC1A2 P43004 1/20 0.72
SLC1A1 P43005 1/20 0.72
GRIA4 P48058 1/20 0.72
GRIN1 Q05586 1/20 0.72
GRIN2A Q12879 1/20 0.72
GRIK2 Q13002 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL3734630 1.00 GRM8 (0.72) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL28761652 0.88 GRM8 (0.72) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL9148962 0.86 GRM8 (0.75) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL9148975 0.86 GRM8 (0.75) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL19900160 0.85 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL26698369 0.85 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL3661546 0.85 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL26621747 0.85 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL2683411 0.85 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL17127348 0.85 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2457896-A1 Tripeptides as caspase modulators Idun Pharmaceuticals, Inc. (US) 2012-05-30 EP disclosed
EP-2457895-A1 Tetrapeptide analogs Idun Pharmaceuticals, Inc. (US) 2012-05-30 EP disclosed
US-20100190688-A1 Tetrapeptide analogs IDUN PHARMACEUTICALS, INC. 2010-07-29 US disclosed
EP-1773348-A4 TETRAPEPTIDE ANALOGS IDUN PHARMACEUTICALS INC (US) 2009-05-20 EP disclosed
EP-1773348-A2 TETRAPEPTIDE ANALOGS Idun Pharmaceuticals, Inc. (US) 2007-04-18 EP disclosed
WO-2006017295-A2 TETRAPEPTIDE ANALOGS IDUN PHARMACEUTICALS, INC. (US) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190688-A1 Tetrapeptide analogs TP53, PCNA, HRAS GRM8 4554/4885GRM6 4512/4885GRM7 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.